abstract |
The invention relates to the use of non-neurotoxic plasminogen activating factors, e.g. from Desmodus rotundus (DSPA) or genetically modified plasminogen activating factors, in particular of human origin, for the manufacture of a medicament for injection for the therapeutic treatment of drops in humans. |